Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Ferrara – page 60

1 201 clinical trials in Ferrara, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Ferrara at a glance
1 201
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 201 trials in Ferrara

Open in trial search

A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Breast cancer+1

Not recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of zoldonrasib in patients with RAS G12D mutation non-small cell lung cancer who have received previous treatment

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zoldonrasib
  • Sponsor:Revolution Medicines Inc.

Alopecia areata

Not recruiting

Study of ritlecitinib for treating severe alopecia areata in children aged 6 to under 12 years

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Sponsor:Pfizer Inc.

Fabry's disease

Not recruiting

Study comparing venglustat tablets with standard therapy for adult patients with Fabry disease and left ventricular hypertrophy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Agalsidase alfa
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of datopotamab deruxtecan with or without durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Arteriosclerosis

Not recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Study comparing valemetostat tosylate plus pembrolizumab versus pembrolizumab alone in patients with advanced non-small cell lung cancer with high PD-L1 expression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Daiichi Sankyo Inc.

Obesity+1

Not recruiting

Study of cagrilintide for weight reduction in adults with overweight or obesity when combined with lifestyle changes

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Ovarian cancer

Not recruiting

Study of Saruparib in Patients with Advanced or Recurrent Ovarian Cancer to Assess Safety and Effectiveness

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Saruparib
  • Sponsor:AstraZeneca AB

Acromegaly

Not recruiting

Study of ALXN2420 with somatostatin analogs for adults with acromegaly to evaluate effectiveness in lowering IGF-1 levels

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2420
  • Sponsor:Alexion Pharmaceuticals Inc.

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Ferrara

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on heart failure prevention and treatment of cardiovascular conditions, including trials testing new therapies for high-risk patients.

  • Heart Failure Prevention
  • Cardiovascular Disease Management
  • Myocardial Infarction Research

Advanced clinical investigations exploring precision medicine approaches and preventive interventions.

02 Oncology Studies

Comprehensive research into various cancer types, including pleural mesothelioma and breast cancer, evaluating novel treatment combinations and therapeutic approaches.

  • Leukemia Treatments
  • Breast Cancer Therapy
  • Lymphoma Management

Focus on improving patient outcomes through targeted therapies and immunotherapy protocols.

03 Immunological Disorders

Studies examining treatments for psoriatic arthritis and other autoimmune conditions, investigating innovative biological therapies.

  • Autoimmune Disease Treatment
  • Respiratory Conditions
  • Inflammatory Disorders

Investigation of novel therapeutic approaches for chronic inflammatory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.